Richard Nolan Townsend Sells 1,127 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 1,127 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $9.27, for a total transaction of $10,447.29. Following the transaction, the chief executive officer owned 240,991 shares in the company, valued at $2,233,986.57. This represents a 0.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Richard Nolan Townsend also recently made the following trade(s):

• On Friday, October 17th, Richard Nolan Townsend sold 13,133 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $8.94, for a total value of $117,409.02.

Lexeo Therapeutics Trading Up 1.7%

LXEO stock opened at $9.06 on Friday. The firm has a 50-day moving average of $8.04 and a two-hundred day moving average of $5.47. Lexeo Therapeutics, Inc. has a one year low of $1.45 and a one year high of $10.38. The firm has a market capitalization of $661.29 million, a PE ratio of -3.36 and a beta of 1.75.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.15. On average, equities research analysts anticipate that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on LXEO shares. HC Wainwright reiterated a “buy” rating on shares of Lexeo Therapeutics in a research note on Monday, November 3rd. Leerink Partners lifted their price target on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Guggenheim assumed coverage on Lexeo Therapeutics in a report on Wednesday, October 15th. They issued a “buy” rating and a $30.00 target price on the stock. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Oppenheimer assumed coverage on shares of Lexeo Therapeutics in a research note on Thursday, July 31st. They issued an “outperform” rating and a $20.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.63.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of LXEO. Vanguard Personalized Indexing Management LLC raised its position in shares of Lexeo Therapeutics by 10.6% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 16,595 shares of the company’s stock worth $110,000 after acquiring an additional 1,595 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Lexeo Therapeutics by 6.1% during the third quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock worth $188,000 after purchasing an additional 1,626 shares in the last quarter. Intech Investment Management LLC grew its stake in Lexeo Therapeutics by 20.7% in the second quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock valued at $55,000 after acquiring an additional 2,342 shares during the period. AXQ Capital LP raised its holdings in Lexeo Therapeutics by 19.6% during the 3rd quarter. AXQ Capital LP now owns 14,921 shares of the company’s stock worth $99,000 after buying an additional 2,446 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Lexeo Therapeutics by 42.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,466 shares of the company’s stock worth $63,000 after purchasing an additional 2,799 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.